Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2022 call → NO我们根据要求判断。管理层是否描述了同类业务规模逐步扩大?在电话会议中,关于Heska协议,Tom Butera提到“总额高达2800万美元的里程碑付款”,并说“除了这些里程碑付款,还有持续的收入”。但这是否是“与公司自身近期过去的比较”?管理层没有明确说之前的交易规模较小,而是说这是“突破性时刻”。关于Discover合同,Terig提到“五份已签署合同,平均约4万美元”,但这是平均,没有说现在比过去大。关于Vet,Heska是第一个大交易,但管理层没有说这是趋势的一部分,而是作为重大成就。没有提到“逐步扩大”或“现在比过去更大”的明确比较。因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.